Comparing two drug combinations for advanced colorectal cancer after first treatment
Part of Cancer, Digestive system clinical trials.
This trial compares two different drug combinations for people with colorectal cancer that has spread and has already been through one round of chemotherapy. One combination uses a newer targeted pill (fruquintinib) while the other uses a standard targeted medicine (bevacizumab), both with chemotherapy. The goal is to see which approach works better as a second-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to other parts of the body (metastatic).
- You have already tried one standard chemotherapy for your cancer, and it either stopped working or caused too many side effects.
- You are between 18 and 75 years old.
- You are generally active and able to care for yourself (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and blood clotting tests are within acceptable limits (the clinic will check this).
- You have not taken irinotecan chemotherapy before, and you have not had certain other drugs (like anti-angiogenesis targeted pills) previously.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
This trial tests two different drug combinations for people with advanced bowel cancer that has a specific genetic change (RAS mutation) and has already been treated with one type of chemotherapy. The goal is to see if one combination works better than the other.
This trial tests two different drug combinations for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if one combination works as well as the other, potentially offering a new option.
This trial compares two different drug combinations for people with advanced colorectal cancer that has grown after first treatment. It tests whether a newer drug (fruquintinib) combined with standard chemotherapy works as well as the current standard (bevacizumab) combined with chemotherapy.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial tests whether the combination of fruquintinib with chemotherapy (trifluridine/tipiracil) works as well as or better than the current standard of bevacizumab with the same chemotherapy for advanced colorectal cancer that has spread. It is for patients who have already had several lines of treatment and are looking for new options.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.